Endocrine disruptors: a new scientific role for clinical pharmacologists? Impact on human health, wildlife, and the environment

It is important for the clinical pharmacologist to understand the potential human health implications of exposure to environmental chemicals that may act as hormonally active agents. It is necessary to have an understanding of how pharmaceutical and personal care products and other chemicals affect the ecosystem of planet Earth and to understand how they may negatively contribute to human disease. Clinical pharmacologists must understand the various definitions of endocrine disruptors and be able to "decipher" these terms for their patients. Understanding the need for the EPA endocrine disruptor screening program and possessing knowledge of the screening assays used to assess endocrine activity potential are two essential components relevant to the topic of endocrine disruptors. Clinical pharmacologists have an opportunity to play an important role in resolving the question of what role endocrine disruptors play in initiating human disease since some scientists argue that the present evidence is not compelling. Clinical pharmacologists can also play an important role in the evaluation of the risk assessment and use of risk management and risk communication tools required to address public health concerns related to actions of endocrine disruptors. It is important that clinical pharmacologists work with veterinary clinical pharmacologists, toxicologists, industrial chemists, regulators, the scientific community, the general public, and environmental groups to understand the impact of endocrine disruptors on human health, wildlife, and the environment with an ultimate goal to minimize and/or alleviate the unwanted, detrimental effects of the endocrine disruptors.

This article has been cited by other articles:

				N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Strom, E. Treuter, M. Warner, et al. Estrogen Receptors: How Do They Signal and What Are Their Targets Physiol Rev, July 1, 2007; 87(3): 905 - 931. [Abstract] [Full Text] [PDF]

				E. Michelini, M. Magliulo, P. Leskinen, M. Virta, M. Karp, and A. Roda Recombinant Cell-Based Bioluminescence Assay for Androgen Bioactivity Determination in Clinical Samples Clin. Chem., October 1, 2005; 51(10): 1995 - 1998. [Full Text] [PDF]

				J. Sanseverino, R. K. Gupta, A. C. Layton, S. S. Patterson, S. A. Ripp, L. Saidak, M. L. Simpson, T. W. Schultz, and G. S. Sayler Use of Saccharomyces cerevisiae BLYES Expressing Bacterial Bioluminescence for Rapid, Sensitive Detection of Estrogenic Compounds Appl. Envir. Microbiol., August 1, 2005; 71(8): 4455 - 4460. [Abstract] [Full Text] [PDF]

				W. J. Biggers and H. Laufer Identification of Juvenile Hormone-Active Alkylphenols in the Lobster Homarus americanus and in Marine Sediments Biol. Bull., February 1, 2004; 206(1): 13 - 24. [Abstract] [Full Text] [PDF]